Celltrion is continuing its expansion into the Nordic market with the entry of its world’s only infliximab subcutaneous (SC) formulation treatment, RemsimaSC (US name: Zimpenetra), into the Danish market.
Remsima SC model exhibited at the European Crohn's and Colitis Organisation (ECCO 2023) event held in Denmark last year [Photo by Lee Chunhee]
On the 18th, Celltrion announced that it recently succeeded in winning the national tender for the autoimmune disease treatment RemsimaSC in Denmark. Accordingly, RemsimaSC will be supplied to Denmark for the next year. This marks RemsimaSC’s successful market entry into Denmark just over two months after winning the national tender in Norway in February, further expanding its presence in the Nordic market.
This tender win is particularly significant as it was conducted through a newly established separate tender by the Danish government. The Danish government recently created a separate national tender specifically for the infliximab subcutaneous injection formulation, the main ingredient of RemsimaSC. Since RemsimaSC is the only infliximab subcutaneous formulation treatment available, Celltrion succeeded in this tender without competition, and an independent distribution channel has now been established. As subcutaneous injection formulations generally command higher prices than intravenous formulations, this is expected to contribute to increased sales and improved performance.
Sales will be directly managed by Celltrion’s Danish subsidiary. The local subsidiary plans to engage in marketing activities to expand product prescriptions immediately after launch. Initially, it will work on securing actual prescription cases of RemsimaSC to enhance product preference among doctors and patients. Prescription data collected from medical sites is expected to have a positive impact not only in Denmark but also in neighboring Nordic countries, so the company plans to focus on strengthening networks with hospitals and medical professionals to facilitate smooth data acquisition. Additionally, the local subsidiary responsible for marketing plans to expand its workforce by the end of this year to strengthen direct sales capabilities.
A Celltrion representative stated, “The Nordic region is characterized by close academic exchanges among neighboring countries, and following the tender success in Norway, winning the tender in Denmark has established a solid foundation for expanding RemsimaSC’s influence.” They added, “Zimpenetra, which was launched in the US last month, has already shown results by completing contracts with pharmacy benefit managers (PBMs) shortly after launch, demonstrating the product’s competitiveness globally. We will do our best to ensure these achievements translate into substantial sales growth.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
